Vident Advisory LLC Acquires 13,232 Shares of Smith & Nephew plc (NYSE:SNN)

Vident Advisory LLC grew its stake in shares of Smith & Nephew plc (NYSE:SNN - Free Report) by 158.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 21,564 shares of the medical equipment provider's stock after acquiring an additional 13,232 shares during the period. Vident Advisory LLC's holdings in Smith & Nephew were worth $530,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Wexford Capital LP bought a new position in shares of Smith & Nephew during the 4th quarter valued at approximately $541,000. Point72 Asset Management L.P. bought a new position in shares of Smith & Nephew during the 4th quarter valued at approximately $6,132,000. Quantinno Capital Management LP grew its position in shares of Smith & Nephew by 83.8% during the 4th quarter. Quantinno Capital Management LP now owns 97,818 shares of the medical equipment provider's stock valued at $2,404,000 after acquiring an additional 44,592 shares during the period. J. Goldman & Co LP bought a new position in shares of Smith & Nephew during the 4th quarter valued at approximately $47,700,000. Finally, D. E. Shaw & Co. Inc. grew its position in shares of Smith & Nephew by 340.6% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 166,587 shares of the medical equipment provider's stock valued at $4,095,000 after acquiring an additional 128,780 shares during the period. 25.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on SNN shares. HSBC downgraded shares of Smith & Nephew from a "buy" rating to a "hold" rating in a research report on Friday, April 25th. Wall Street Zen raised shares of Smith & Nephew from a "buy" rating to a "strong-buy" rating in a report on Wednesday, February 26th. Hsbc Global Res downgraded shares of Smith & Nephew from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Canaccord Genuity Group raised their price objective on shares of Smith & Nephew from $27.00 to $28.00 and gave the stock a "hold" rating in a report on Thursday, May 1st. Finally, UBS Group downgraded shares of Smith & Nephew from a "buy" rating to a "neutral" rating in a report on Wednesday, March 12th. Six analysts have rated the stock with a hold rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $28.00.

Smith & Nephew Price Performance

NYSE SNN traded up $0.12 on Friday, hitting $28.94. The stock had a trading volume of 323,630 shares, compared to its average volume of 792,949. Smith & Nephew plc has a 52-week low of $23.69 and a 52-week high of $31.72. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. The company has a market capitalization of $12.67 billion, a price-to-earnings ratio of 13.40, a price-to-earnings-growth ratio of 1.26 and a beta of 0.68. The firm has a 50-day moving average of $27.47 and a 200-day moving average of $26.49.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.